RxDoctor Payments Data

Mohammad Malik, DPM

Foot & Ankle Surgery · Philadelphia, PANPI 1841600053

Payments from drug & device makers

$3,264in general payments, 2019–2025

Across 96 payments — averaging $34.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$838
  • Stryker$601
  • Averitas Pharma Inc.$420
  • Treace Medical Concepts, Inc.$300
  • Zimmer Biomet$187
  • Organogenesis Inc.$145
  • plus $773 from 19 others

What the payments were for

  • Food & beverage$3,264100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,264 in reported general payments places this provider in the 55th percentile of 575 foot & ankle surgery providers in Pennsylvania.

See all foot & ankle surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$83,199
Medicare patients
396
Services billed
1,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.16$34,928
Ammonium Lactate258$4,312
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip106$2,671
Clobetasol Propionate25$2,664
Diclofenac Sodium72$1,809
Ciclopirox37$1,218
Gabapentin154$1,157
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort20$1,018
NyamycNystatin28$613
Mupirocin64$538
Pregabalin31$435
Triamcinolone Acetonide88$406
Doxycycline Hyclate35$265
Terbinafine Hcl15$210
Nystatin16$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$838$34,92816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 575 foot & ankle surgery providers in Pennsylvania.

Other foot & ankle surgery in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →